Nutraceuticals as Ligands of PPARγ

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear receptors that respond to several exogenous and endogenous ligands by modulating genes related to lipid, glucose, and insulin homeostasis. PPARγ, expressed in adipose tissue and liver, regulates lipid storage and glucos...

Full description

Bibliographic Details
Main Authors: Meera Penumetcha, Nalini Santanam
Format: Article
Language:English
Published: Hindawi Limited 2012-01-01
Series:PPAR Research
Online Access:http://dx.doi.org/10.1155/2012/858352
id doaj-ef1a07a8a5e14b1b81c8783681c0861e
record_format Article
spelling doaj-ef1a07a8a5e14b1b81c8783681c0861e2020-11-24T22:01:16ZengHindawi LimitedPPAR Research1687-47571687-47652012-01-01201210.1155/2012/858352858352Nutraceuticals as Ligands of PPARγMeera Penumetcha0Nalini Santanam1Division of Nutrition, BFLSON and Health Professions, Urban Life Building, 140 Decatur Street, Suite 862, Atlanta, GA 30303, USADepartment of Pharmacology, Physiology and Toxicology, Joan C Edwards School of Medicine, Marshall University, One John Marshall Drive, Huntington, WV 25755, USAPeroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear receptors that respond to several exogenous and endogenous ligands by modulating genes related to lipid, glucose, and insulin homeostasis. PPARγ, expressed in adipose tissue and liver, regulates lipid storage and glucose metabolism and is the target of type 2 diabetes drugs, thiazolidinediones (TZDs). Due to high levels of toxicity associated with the first generation TZDs, troglitazone (Rezulin), rosiglitazone (Avandia), and pioglitazone (Actos), there is a renewed search for newer PPAR drugs that exhibit better efficacy but lesser toxicity. In recent years, there has been a definite increase in the consumption of dietary supplements among diabetics, due to the possible health benefits associated with these nutraceutical components. With this impetus, investigations into alternative natural ligands of PPARs has also risen. This review highlights some of the dietary compounds (dietary lipids, isoflavones, and other flavanoids) that bind and transactivate PPARγ. A better understanding of the physiological effects of this PPAR activation by nutraceuticals and the availability of high-throughput technologies should lead to the discovery of less toxic alternatives to the PPAR drugs currently on the market.http://dx.doi.org/10.1155/2012/858352
collection DOAJ
language English
format Article
sources DOAJ
author Meera Penumetcha
Nalini Santanam
spellingShingle Meera Penumetcha
Nalini Santanam
Nutraceuticals as Ligands of PPARγ
PPAR Research
author_facet Meera Penumetcha
Nalini Santanam
author_sort Meera Penumetcha
title Nutraceuticals as Ligands of PPARγ
title_short Nutraceuticals as Ligands of PPARγ
title_full Nutraceuticals as Ligands of PPARγ
title_fullStr Nutraceuticals as Ligands of PPARγ
title_full_unstemmed Nutraceuticals as Ligands of PPARγ
title_sort nutraceuticals as ligands of pparγ
publisher Hindawi Limited
series PPAR Research
issn 1687-4757
1687-4765
publishDate 2012-01-01
description Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear receptors that respond to several exogenous and endogenous ligands by modulating genes related to lipid, glucose, and insulin homeostasis. PPARγ, expressed in adipose tissue and liver, regulates lipid storage and glucose metabolism and is the target of type 2 diabetes drugs, thiazolidinediones (TZDs). Due to high levels of toxicity associated with the first generation TZDs, troglitazone (Rezulin), rosiglitazone (Avandia), and pioglitazone (Actos), there is a renewed search for newer PPAR drugs that exhibit better efficacy but lesser toxicity. In recent years, there has been a definite increase in the consumption of dietary supplements among diabetics, due to the possible health benefits associated with these nutraceutical components. With this impetus, investigations into alternative natural ligands of PPARs has also risen. This review highlights some of the dietary compounds (dietary lipids, isoflavones, and other flavanoids) that bind and transactivate PPARγ. A better understanding of the physiological effects of this PPAR activation by nutraceuticals and the availability of high-throughput technologies should lead to the discovery of less toxic alternatives to the PPAR drugs currently on the market.
url http://dx.doi.org/10.1155/2012/858352
work_keys_str_mv AT meerapenumetcha nutraceuticalsasligandsofpparg
AT nalinisantanam nutraceuticalsasligandsofpparg
_version_ 1725840622629158912